-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Today, Regeneron and Sanofi announced that Dupixent, a blockbuster IL-4/IL-13 inhibitor, reached the dual primary endpoint in the second clinical trial for the treatment of eosinophilic esophagitis (EoE)
Eosinophilic esophagitis is a chronic, progressive type 2 inflammatory disease that damages the esophagus and causes it to not work properly
Dupixent is a fully humanized monoclonal antibody that can inhibit the signal transduction of interleukin 4 (IL-4) and interleukin 13 (IL-13) proteins
▲The mechanism of Dupixent (picture source: Sanofi official website)
The results of this phase 3 clinical trial showed that after 24 weeks of treatment:
Symptoms of the disease in the Dupixent group were reduced by 64% compared to baseline compared to 41% in the placebo group (p=0.
59% of patients in the Dupixent group achieved histological disease remission, which was nearly 10 times that of the placebo group (6%) (p<0.
In terms of safety, the results of this clinical trial are consistent with the safety characteristics of Dupixent in the approved indications
Reference materials:
[1] SECOND DUPIXENT® (DUPILUMAB) PHASE 3 EOSINOPHILIC ESOPHAGITIS TRIAL TO DEMONSTRATE SIGNIFICANT DISEASE IMPROVEMENTS, UNDERSCORING ROLE OF TYPE 2 INFLAMMATION IN THIS COMPLEX DISEASE.
